Related coverage linked through entity extraction aliases.
Mar 12, 2026
Pembrolizumab-based regimens demonstrated significant survival improvements in two separate trials: KEYNOTE-B15 for muscle-invasive bladder cancer and KEYNOTE-B96 for platinum-resistant ovarian cancer, with FDA approval granted for the ovarian cancer indication.
Mar 10, 2026
BriaCell Therapeutics announced an asset purchase agreement transferring its Soluble CD80 license to majority-owned subsidiary BriaPro, while four abstracts were accepted for presentation at the 2026 AACR Annual Meeting.
Feb 27, 2026
A clinical trial combining laser interstitial thermal therapy with pembrolizumab shows nearly half of patients with recurrent high-grade astrocytoma alive at 18 months, compared to zero in the control group.
Feb 24, 2026
The FDA has granted fast track designation to ART6043 plus olaparib for germline BRCA-mutated HER2-negative breast cancer and to BriaCell's Bria-IMT plus immune checkpoint inhibitor for metastatic breast cancer, both addressing significant unmet medical needs.
Feb 20, 2026
PDS Biotechnology adopted an amended protocol for its Phase 3 VERSATILE-003 trial, adding progression-free survival as an interim primary endpoint to support potential accelerated approval of PDS0101 in HPV16-positive head and neck cancer.
Feb 13, 2026
A randomized trial of 210 advanced lung cancer patients found that administering checkpoint inhibitor immunotherapy in the morning nearly doubled progression-free survival and extended overall survival by nearly a year compared to later-day dosing.
